Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236543 | 0.79 | MTNR1A (0.47) | NOTUMHSD17B3 | |
| SCHEMBL7905314 | 0.77 | HTR2C (0.40) | AHRPNMTHTR2AHTR2CHTR2B | |
| SCHEMBL13889887 | 0.73 | GAA (0.42) | HDAC8AHRNOTUMIDO1TDO2 | |
| SCHEMBL2732954 | 0.67 | PNMT (0.53) | HDAC8PNMT | |
| SCHEMBL31369850 | 0.67 | PNMT (0.45) | PNMT | |
| SCHEMBL31553578 | 0.67 | PNMT (0.53) | HDAC8PNMT | |
| SCHEMBL6615945 | 0.67 | MEN1 (0.68) | HTR2A | |
| SCHEMBL6633687 | 0.67 | MEN1 (0.68) | HTR2A | |
| Hydrochloric Acid SCHEMBL32676699 | 0.66 | PNMT (0.51) | HDAC8PNMT | |
| SCHEMBL20582071 | 0.66 | AHR (0.54) | AHRPNMTTGM2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6503900-B2 | For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-04 | — | — | US | disclosed |
| WO-2002036596-A2 | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | GRIK1, GRIK3, GRIK4 | HDAC8 244/4885AHR 164/4885PNMT 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.